Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Rezolute stock

RZLT
US76200L3096

Price

0
Today +/-
-0
Today %
-0 %

Rezolute stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Rezolute stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Rezolute stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Rezolute stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Rezolute's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Rezolute Stock Price History

DateRezolute Price
11/28/20240 undefined
11/27/20240 undefined
11/26/20240 undefined
11/25/20240 undefined
11/22/20240 undefined
11/21/20240 undefined
11/20/20240 undefined
11/19/20240 undefined
11/18/20240 undefined
11/15/20240 undefined
11/14/20240 undefined
11/13/20240 undefined
11/12/20240 undefined
11/11/20240 undefined
11/8/20240 undefined
11/7/20240 undefined
11/6/20240 undefined
11/5/20240 undefined
11/4/20240 undefined
11/1/20240 undefined
10/31/20240 undefined
10/30/20240 undefined

Rezolute Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rezolute, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rezolute from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rezolute’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rezolute. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rezolute’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rezolute’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rezolute’s growth potential.

Rezolute Revenue, EBIT and net profit per share

DateRezolute RevenueRezolute EBITRezolute Net Income
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined

Rezolute Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000000000000000000
---------------------
---------------------
000000000000000000000
000000000000000000000
---------------------
000000000000000000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Rezolute Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Rezolute is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021202220232024
                           
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
                           
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
00000000000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Rezolute provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Rezolute's financial health and stability.

Assets

Rezolute's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Rezolute must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Rezolute after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Rezolute's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
-------------
0000000000000
0000000000000
0000000000000
0000000000000

Rezolute stock margins

The Rezolute margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rezolute. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rezolute.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rezolute's sales revenue. A higher gross margin percentage indicates that the Rezolute retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rezolute's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rezolute's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rezolute's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rezolute. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rezolute's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rezolute Margin History

Rezolute Gross marginRezolute Profit marginRezolute EBIT marginRezolute Profit margin
2030e0 %0 %0 %
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %

Rezolute Stock Sales Revenue, EBIT, Earnings per Share

The Rezolute earnings per share therefore indicates how much revenue Rezolute has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rezolute earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rezolute's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rezolute’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rezolute's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rezolute Revenue, EBIT and net profit per share

DateRezolute Sales per ShareRezolute EBIT per shareRezolute Earnings per Share
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined

Rezolute business model

Rezolute Inc. is a bio-pharmaceutical company that was founded in 2010 in California. The company specializes in the research and development of innovative therapies for the treatment of rare metabolic and endocrine diseases. The business model of Rezolute is to develop innovative solutions and treatment approaches for diseases that currently have insufficient treatment options. The company is actively working to expand its product pipeline and explore new treatment methods in order to give hope and prospects for a better quality of life to suffering patients. Rezolute is active in three main areas: diabetes and metabolic diseases, diseases of the endocrine system, and protein-based therapy platforms. Each of these areas is of great importance in combating rare diseases that are often overlooked by the pharmaceutical industry. The diabetes and metabolic diseases category is the core business of Rezolute Inc. The company strives to develop innovative therapies for the treatment of diabetes itself and its comorbidities. This includes diseases of the cardiovascular system and kidney diseases, which are common among diabetes patients. In the category of endocrine diseases, the company is working on the development of targeted therapies for the treatment of diseases such as hypothyroidism (an underactive thyroid) and hypopituitarism (a deficiency of hormones produced by the pituitary gland). These diseases are often overlooked by the pharmaceutical industry as they occur less frequently compared to other diseases. The protein-based therapy platforms are technologically advanced and have the potential to offer new treatment options. Rezolute utilizes its own proprietary technologies for the development of immunoglobulins and drugs that specifically target certain molecules. The company is also researching compounds that can influence the immune system to combat inflammation and autoimmune diseases. Rezolute currently has several therapy options in development. The company is working on RZ358, an oral insulin formulation for the treatment of diabetes; RZ402, a drug for the treatment of pancreatitis (inflammation of the pancreas); and RZ402, a drug for the treatment of pancreatitis (inflammation of the pancreas). The company has also obtained orphan drug status to develop RZ358, its innovative therapy for the treatment of Congenital Hyperinsulinism (CHI), a rare, congenital endocrine disorder. Rezolute has established itself as an important player in the global bio-pharmaceutical market. The company is committed to improving the lives of patients suffering from rare diseases by developing innovative treatment options. With a dedicated team of scientists and researchers, the company strives to push the boundaries of science and develop the next generation of innovative therapies that have the potential to improve the lives of patients. Rezolute is one of the most popular companies on Eulerpool.com.

Rezolute SWOT Analysis

Strengths

Rezolute Inc has a strong and experienced management team that brings expertise in the biopharmaceutical industry.

The company has a diverse product pipeline, with several candidates in different stages of development, which provides potential for future growth.

Weaknesses

Rezolute Inc operates in a highly competitive industry, facing competition from established players with greater resources.

The company is relatively smaller in size and has limited financial resources, which may restrict its ability to fully execute on its pipeline.

Opportunities

The increasing demand for innovative therapeutic solutions presents an opportunity for Rezolute Inc to capture market share with its unique products in development.

Strategic partnerships and collaborations can provide access to additional resources, expertise, and potentially accelerate development and commercialization.

Threats

Regulatory challenges and the lengthy approval process pose a threat, potentially delaying market entry and putting pressure on financial resources.

The uncertainty surrounding healthcare policies and reimbursement systems can impact market access and pricing for Rezolute Inc's products.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Rezolute Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Rezolute historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Rezolute shares outstanding

The number of shares was Rezolute in 2023 — This indicates how many shares 51.19 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rezolute earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rezolute's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rezolute’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rezolute's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rezolute stock splits

In Rezolute's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Rezolute.

Rezolute latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240 0  (34.64 %)2025 Q1
6/30/20240 0  (-32.49 %)2024 Q4
3/31/20240 0  (-9.54 %)2024 Q3
12/31/20230 0  (12.73 %)2024 Q2
9/30/20230 0  (2.81 %)2024 Q1
6/30/20230 0  (31.15 %)2023 Q4
3/31/20230 0  (1.96 %)2023 Q3
12/31/20220 0  (19.85 %)2023 Q2
9/30/20220 0  (50.66 %)2023 Q1
6/30/20220 0  (10.65 %)2022 Q4
1
2
3

Rezolute shareholders

%
Name
Stocks
Change
Date
13.35049 % Federated Hermes Global Investment Management Corp.7,735,274-3,544,05310/7/2024
12.41391 % Handok Inc7,192,6171,250,00010/7/2024
5.16045 % Nantahala Capital Management, LLC2,989,963-32,9846/30/2024
4.82862 % Vivo Capital, LLC2,797,70406/30/2024
3.56224 % Adar1 Capital Management LLC2,063,9622,063,9626/30/2024
3.19296 % Affinity Asset Advisors LLC1,850,000250,0006/30/2024
3.01111 % Blackstone Alternative Asset Management, L.P.1,744,640206,9566/30/2024
2.94788 % Sphera Funds Management Ltd.1,707,999711,2896/30/2024
2.93407 % Altium Capital Management LP1,700,0001,700,0006/30/2024
2.79261 % The Vanguard Group, Inc.1,618,03664,6846/30/2024
1
2
3
4
5
...
9

Rezolute Executives and Management Board

Mr. Nevan Elam

(55)
Rezolute Acting Chairman of the Board, Chief Executive Officer (since 2013)
Compensation 973,646

Dr. Brian Roberts

(48)
Rezolute Chief Medical Officer
Compensation 738,858

Mr. Gilbert Labrucherie

(52)
Rezolute Independent Director
Compensation 69,000

Mr. Philippe Fauchet

(65)
Rezolute Independent Director
Compensation 66,000

Dr. Wladimir Hogenhuis

(58)
Rezolute Independent Director
Compensation 64,000
1
2

Most common questions regarding Rezolute

What values and corporate philosophy does Rezolute represent?

Rezolute Inc represents values such as innovation, dedication, and integrity. The company focuses on developing novel therapies and solutions for patients with chronic and rare diseases. Rezolute Inc's corporate philosophy is centered around prioritizing patient well-being and improving their quality of life through cutting-edge research and development. With a strong emphasis on scientific excellence and collaboration, Rezolute Inc strives to provide groundbreaking medical solutions that address unmet medical needs.

In which countries and regions is Rezolute primarily present?

Rezolute Inc primarily operates in the United States.

What significant milestones has the company Rezolute achieved?

Rezolute Inc has achieved several significant milestones in its operations. One notable achievement is the successful completion of its Phase 1 clinical trial for its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). This milestone demonstrated the safety and tolerability of RZ358 and its potential to treat CHI, a rare genetic disorder. Additionally, the company has obtained orphan drug designation from the FDA for RZ358, providing it with exclusive market rights and potential financial incentives. Rezolute Inc has also entered into strategic partnerships and collaborations with renowned institutions, accelerating the development and commercialization of its innovative therapeutics.

What is the history and background of the company Rezolute?

Rezolute Inc is a pharmaceutical company founded in 2010. It focuses on the development of therapeutics for chronic diseases like diabetes and rare genetic disorders. Rezolute is committed to providing innovative and effective solutions to improve patient outcomes in these areas. With a dedicated team of experts, the company utilizes cutting-edge technologies to advance its pipeline of drug candidates. Rezolute's history is marked by strategic collaborations and partnerships with leading industry players, reinforcing its position as a promising player in the biopharmaceutical sector. Through its continuous efforts, Rezolute aims to make a significant impact on the lives of patients worldwide.

Who are the main competitors of Rezolute in the market?

The main competitors of Rezolute Inc in the market include companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Pfizer Inc. These companies also operate in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of innovative therapies. Rezolute Inc competes with these industry leaders by offering its unique portfolio of products and striving to provide effective solutions to patients in need.

In which industries is Rezolute primarily active?

Rezolute Inc is primarily active in the pharmaceutical industry.

What is the business model of Rezolute?

The business model of Rezolute Inc. revolves around developing and commercializing innovative therapies for people with rare and severe chronic disorders. Rezolute focuses on delivering transformative treatments by leveraging their expertise in protein engineering and drug development. The company aims to address unmet medical needs through the discovery, development, and successful commercialization of therapies. Rezolute Inc. utilizes strategic collaborations, licensing agreements, and partnerships to further advance their product portfolio and accelerate their development timelines, delivering potential value to patients, healthcare providers, and shareholders.

What is the P/E ratio of Rezolute 2024?

The P/E ratio cannot be calculated for Rezolute at the moment.

What is the P/S ratio of Rezolute 2024?

The P/S cannot be calculated for Rezolute currently.

What is the Quality Investing of Rezolute?

The Quality Investing for Rezolute is 4/10.

What is the revenue of Rezolute 2024?

The revenue cannot currently be calculated for Rezolute.

How high is the profit of Rezolute 2024?

The profit cannot currently be calculated for Rezolute.

What is the business model of Rezolute

The company Rezolute Inc is a US-based biopharmaceutical company that focuses on the discovery and development of new therapeutics for rare endocrine and metabolic disorders. The business model of Rezolute Inc is based on deep biological and medical expertise, high standards for clinical development, and efficient project management to bring new biopharmaceutical products to the market. Rezolute Inc has two main divisions that focus on the discovery and development of drugs suitable for rare endocrine and metabolic disorders. The first division is engaged in the development of peptide and monoclonal antibody drugs for the treatment of congenital hyperinsulinism, diabetes mellitus, and other insulin-resistant diseases. The second division focuses on the discovery and development of drugs for the treatment of rare metabolic diseases such as lysosomal storage diseases, cellular metabolic disorders, and mitochondrial diseases. Rezolute Inc aims to improve the quality of life for patients with rare diseases. To achieve this, the company develops new compounds and products that provide effective and safe therapies for these diseases. Rezolute Inc utilizes a combination of traditional and innovative technologies to maximize the efficacy and safety of new therapeutics. The company works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide. Rezolute Inc has several products in the pipeline that are expected to be released soon. These include RZ358, an oral drug for the treatment of congenital hyperinsulinism, and RZ402, an oral drug for the treatment of metabolic disorders. Additionally, the company is working on the clinical development of RZ358 for the treatment of diabetes mellitus, a chronic metabolic disorder that affects millions of people worldwide. In addition to its development activities, Rezolute Inc conducts extensive research and development to identify and develop innovative therapeutic technologies. The company has formed partnerships with academic research institutions, hospitals, and pharmaceutical companies around the world to expand its knowledge and expertise in this area. In summary, Rezolute Inc is a biopharmaceutical company dedicated to the development of therapies for rare endocrine and metabolic disorders. The company uses a combination of traditional and innovative technologies and has an extensive product pipeline tailored to the needs of patients. Rezolute Inc works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide.

What is the Rezolute dividend?

Rezolute pays a dividend of 0 USD distributed over payouts per year.

How often does Rezolute pay dividends?

The dividend cannot currently be calculated for Rezolute or the company does not pay out a dividend.

What is the Rezolute ISIN?

The ISIN of Rezolute is US76200L3096.

What is the Rezolute ticker?

The ticker of Rezolute is RZLT.

How much dividend does Rezolute pay?

Over the past 12 months, Rezolute paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rezolute is expected to pay a dividend of 0 USD.

What is the dividend yield of Rezolute?

The current dividend yield of Rezolute is .

When does Rezolute pay dividends?

Rezolute pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rezolute?

Rezolute paid dividends every year for the past 0 years.

What is the dividend of Rezolute?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rezolute located?

Rezolute is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rezolute kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rezolute from 11/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.

When did Rezolute pay the last dividend?

The last dividend was paid out on 11/28/2024.

What was the dividend of Rezolute in the year 2023?

In the year 2023, Rezolute distributed 0 USD as dividends.

In which currency does Rezolute pay out the dividend?

The dividends of Rezolute are distributed in USD.

All fundamentals about Rezolute

Our stock analysis for Rezolute Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rezolute Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.